SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Howard H. Pien to the company’s board of directors.
“Howard is a seasoned industry leader with deep biopharmaceutical expertise, especially in guiding companies as they expand and evolve from research and development to clinical stage,” said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
